KAF 156 + lumefantrine trial launched in Mali to treat malaria.- Novartis
Novartis and Medicines for Malaria Venture (MMV) have launched a patient trial for KAF 156, a next-generation antimalarial compound with the potential to treat drug-resistant strains of the malaria parasite. The trial will test the efficacy of KAF 156 in combination with a new, improved formulation of the existing antimalarial lumefantrine. The first trial center is operational in Mali and will be followed by sixteen additional centers across a total of nine countries in Africa and Asia over the next few months.
Next-generation antimalarials are urgently needed to tackle rising parasite resistance to current therapies. Emergence of resistance to both artemisinin and many partner drugs has been reported in Asia and reduced sensitivity to artemisinin has also been sporadically reported in Africa. The phase IIb study will test multiple dosing combinations and dosing schedules of KAF 156 and lumefantrine, including the feasibility of a single dose therapy in adults, adolescents and children. As children are the most vulnerable to malaria, the goal is to include them in the clinical trial as quickly as possible, following safety review of the data generated in adults, thereby potentially accelerating the development of a pediatric formulation. It is important to test new drug candidates in the settings where they will be used. Conducted in state-of-the-art centers across Africa and Asia, the KAF 156 trial is particularly complex given that multiple dosing combinations and dosing schedules are being tested in parallel in three different age groups.
KAF 156 is the result of a Wellcome Trust, MMV and Singapore Economic Development Board supported joint research program with the Novartis Institute for Tropical Diseases, the Genomics Institute of the Novartis Research Foundation, and the Swiss Tropical and Public Health Institute. Novartis is developing KAF 156 with scientific and financial support from MMV (in collaboration with the Bill & Melinda Gates Foundation).
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins